-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US60365F1093 |
| Sector | Healthcare |
| Industry | Health Information Services |
| Market Cap | 4B |
|---|---|
| PE Ratio | None |
| Target Price | 22.4546 |
| Beta | nan |
| Dividend Yield | None |
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera, or Guardian 4, and wraparound applications and services. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. Minimed Group, Inc. operates independently of Medtronic Global Holdings S.C.A. as of March 25, 2026.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for MMED using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026